Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCO-940
- Development stage
- Preclinical
- Lead developer
- SCOHIA PHARMA
- Modality
- Peptides
01
Overview
SCO-940 (also known as CT-G32) is a first-in-class quadruple agonist being developed by Scohia Pharma in collaboration with Celltrion for the treatment of obesity and metabolic diseases. Positioned as a next-generation therapy, it aims to provide superior appetite suppression and weight loss compared to existing dual- or triple-agonist treatments. Scohia Pharma is responsible for discovery and preclinical research, while Celltrion handles clinical development, regulatory affairs, manufacturing, and commercialization. The program is currently in the preclinical stage, with an Investigational New Drug (IND) application targeted for the first half of 2027.
- Other names
- Novel Quadruple Agonist
Beyond the preview
Go deeper on SCO-940.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCO-940.